Case report: Ravulizumab successfully treated COVID-19-triggered complement-mediated TMA in a kidney transplant recipient
Doctors report a single case where ravulizumab treated a rare blood disorder after COVID-19 in a kidney transplant patient.
A case report describes a 75-year-old kidney transplant recipient who developed complement-mediated thrombotic microangiopathy (CM-TMA) trig…
A kidney transplant patient with COVID-19 improved after doctors treated a rare blood disorder with ravulizumab, showing age shouldn't block…
